



7 February 2017

Motif Bio plc
 ("Motif Bio" or the "Company")

Notification and public disclosure of transactions by PDMR and persons closely associated with them

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that on 6 February 2017 it was notified that Amphion Innovations plc ("Amphion") had pledged an additional 14,500,000 ordinary shares of 1 penny each in the capital of Motif Bio as security to a draw-down of an additional tranche of Amphion's loan facility (the "Share Pledge"). In total, Amphion has pledged 42,461,625 ordinary shares in the Company in relation to the Share Pledge. As a result of the Share Pledge, Amphion will transfer legal title to but will retain the beneficial interest in these pledged ordinary shares. Richard Morgan and Robert Bertoldi, non-executive Chairman and executive director of the Company respectively, are also directors of Amphion (the "Amphion Directors"). Amphion is therefore a "Person Closely Associated" with the Amphion Directors under the Market Abuse Regulation. The Share Pledge does not change the number of ordinary shares of the Company in issue.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Amphion Innovations Plc
2	Reason for the notification	
a)	Position/status	Person Closely Associated with PDMRs of Motif Bio Plc (Robert Bertoldi and Richard Morgan)
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Motif Bio Plc
b)	LEI	54930080DN00QTIUUU84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares ISIN GB00BVVT4H71
b)	Nature of the transaction	Transfer of the legal but not beneficial interest in 14,500,000 Ordinary Shares by way of a pledge for a loan

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		N/A	14,500,000
d)	Aggregated information	Price(s)	Volume(s)
		N/A	14,500,000
e)	Date of the transaction	6 February 2017	
f)	Place of the transaction	N/A	

For further information please contact:

Motif Bio plc

Graham Lumsden (Chief Executive Officer)

info@motifbio.com

Zeus Capital Limited (NOMAD & BROKER)

Phil Walker/Giles Balleny

Dominic Wilson

+44 (0)20 3829 5000

Northland Capital Partners Limited (BROKER)

Patrick Claridge/ David Hignell

John Howes/ Rob Rees (Broking)

+44 (0)203 861 6600

Walbrook PR Ltd. (FINANCIAL PR & IR)

Paul McManus

Mike Wort

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

MC Services AG (EUROPEAN IR)

Raimund Gabriel

+49 (0)89 210 2280